Pathophysiology of Myelodysplastic Syndromes (MDS)
- MDS is a clonal disorder that arises from the expansion of hematopoietic stem cells (HSCs)Sekeres MA, Taylor J. JAMA. 2022;328:872-880. Hoff FW, Madanat YF. Cells. 2023;12:627.
- The somatic mutations that drive MDS confer selective survival advantage over wild-type cells, and the enhanced self-renewal leads to the accumulation of clonal hematopoiesis over time, resulting in abnormal progenitor and precursor cellsSekeres MA, Taylor J. JAMA. 2022;328:872-880. Hoff FW, Madanat YF. Cells. 2023;12:627.
- Terminal maturation is impaired, leading to increased apoptosis of differentiating cells and, thus, peripheral cytopeniasSekeres MA, Taylor J. JAMA. 2022;328:872-880. Hoff FW, Madanat YF. Cells. 2023;12:627. Sperling AS et al. Nat Rev Cancer. 2017;17:5-19.
- In 30% of cases, MDS can progress to acute myeloid leukemia (AML) because of the accumulation of additional mutationsHoff FW, Madanat YF. Cells. 2023;12:627.
Ineffective hematopoiesis in MDSSekeres MA, Taylor J. JAMA. 2022;328:872-880. Hellström-Lindberg E et al. Haematologica. 2020;105:1765-1779. Adès L et al. Lancet. 2014;383:2239-2252.
MDS cells accumulate in the bone marrow as a result of a complex interplay between genetic and epigenetic alterations, the bone marrow microenvironment, and the immune system, a process that can develop over several yearsHellström-Lindberg E et al. Haematologica. 2020;105:1765-1779. Hasserjian RP et al. Virchows Arch. 2023;482:39-51.
HSC, hematopoietic stem cell.
An initiating driver mutation occurs in an HSC, giving rise to clonal hematopoiesis of mutant stem cells and abnormal progenitor and precursor cellsSekeres MA, Taylor J. JAMA. 2022;328:872-880.
Clonal hematopoiesis of indeterminate potential (CHIP) is defined by the presence of a somatic mutation in a myeloid neoplasm driver gene or a non-MDS-defining clonal cytogenetic aberration, in a patient with no known myeloid neoplasm and no unexplained cytopeniaHasserjian RP et al. Virchows Arch. 2023;482:39-51.
HSC, hematopoietic stem cell.
Acquisition of additional somatic genetic variants may occur over decades and result in impaired differentiation capacity and progressive dysplasiaSekeres MA, Taylor J. JAMA. 2022;328:872-880.
Clonal cytopenia of undetermined significance (CCUS) is a precursor to MDS, in which mutation in ≥ 1 myeloid-associated genes is accompanied by persistent (≥ 4 months) cytopeniaHasserjian RP et al. Virchows Arch. 2023;482:39-51.
MEP, megakaryocyte-erythroid progenitor; GMP, granulocyte-monocyte progenitor.
Increased proliferation of immature blood cells and loss of mature circulating cells result in cytopeniaSperling AS et al. Nat Rev Cancer. 2017;17:5-19.
MDS are characterized by clonal hematopoiesis and abnormal maturation of hematopoietic cells resulting in cytopeniaHasserjian RP et al. Virchows Arch. 2023;482:39-51.
Lastly, MDS can convert to AML when there is a leukemic transformation that results in excessive immature white blood cell formationVeiga CB et al. Cancers (Basel). 2021;13:1968.
Multiple chromosomal abnormalities and genetic mutations have been identified to cause MDSVeiga CB et al. Cancers (Basel). 2021;13:1968.
- Approximately half of patients with MDS harbor chromosomal abnormalities affecting copy number alteration (eg, deletion, monosomy, or trisomy) or, more rarely, leading to a structural change (eg, balanced translocation or inversion)Hoff FW, Madanat YF. Cells. 2023;12:627.
- The most common chromosomal abnormality is del(5q), which is present in up to 15% of patientsHoff FW, Madanat YF. Cells. 2023;12:627.
- Up to 30% of patients with MDS exhibit a complex karyotype (≥ 3 cytogenetic abnormalities), which is associated with a higher risk of progression to AML and a very poor prognosisHoff FW, Madanat YF. Cells. 2023;12:627.
Most common cytogenetic mutations in MDSHoff FW, Madanat YF. Cells. 2023;12:627. Saygin C, Godley LA. Cancers (Basel). 2021;13:3380.
del, deletion.
- Whole-exome sequencing technologies have enabled detection of recurrent somatic mutations in > 50 genes in up to 90% of MDS casesSaygin C, Godley LA. Cancers (Basel). 2021;13:3380.
- Target driver gene mutations are involved in a variety of functional pathways, as shown belowSaygin C, Godley LA. Cancers (Basel). 2021;13:3380.
Landscape of somatic mutations in MDSHoff FW, Madanat YF. Cells. 2023;12:627. Tobiasson M, Kittang AO. J Intern Med. 2019;286:41-62.
Click the magnify icon to enlarge
Adapted with permission from J Intern Med.Tobiasson M, Kittang AO. J Intern Med. 2019;286:41-62.
DNA, deoxyribonucleic acid; mRNA, messenger RNA; RNA, ribonucleic acid.
Frequency of driver gene mutations in MDSHoff FW, Madanat YF. Cells. 2023;12:627. Nazha A, eds. Diagnosis and Management of Myelodysplastic Syndromes: A Clinical Guide. Springer; 2020.
Click the magnify icon to enlarge
Adapted with permission from Springer.Nazha A, eds. Diagnosis and Management of Myelodysplastic Syndromes: A Clinical Guide. Springer; 2020.
Recurrently mutated genes in MDS, categorized according to biological function and mutation frequency. Circle size correlates with mutation frequency; light-colored halos indicate the upper limit of frequency. Mutations that confer an IPSS-R—independent negative effect are colored in orange; mutations with no clear independent effect are displayed as gray/light gray circles. Only SF3B1 mutations are associated with a favorable prognosis (yellow).Nazha A, eds. Diagnosis and Management of Myelodysplastic Syndromes: A Clinical Guide. Springer; 2020.
DNA, deoxyribonucleic acid; IPSS-R, Revised International Prognostic Scoring System; RNA, ribonucleic acid.
